ndividuals with spontaneous loss-of-function PCSK9 mutations experience a significant reduction of both LDL-C levels (30–40%) as well as CHD risk (88%), and appear free from adverse clinical consequences.2 Gene-editing technologies, which include the CRISPR–Cas nucleases and CRISPR base editor, have the potential to permanently modify disease-causing genes.

A 'once-and-done' approach to the lifelong reduction of elevated cholesterol / Paneni, Francesco; Volpe, Massimo. - In: EUROPEAN HEART JOURNAL. - ISSN 1522-9645. - 42:37(2021), pp. 3820-3821. [10.1093/eurheartj/ehab478]

A 'once-and-done' approach to the lifelong reduction of elevated cholesterol

Paneni, Francesco;Volpe, Massimo
2021

Abstract

ndividuals with spontaneous loss-of-function PCSK9 mutations experience a significant reduction of both LDL-C levels (30–40%) as well as CHD risk (88%), and appear free from adverse clinical consequences.2 Gene-editing technologies, which include the CRISPR–Cas nucleases and CRISPR base editor, have the potential to permanently modify disease-causing genes.
File allegati a questo prodotto
File Dimensione Formato  
Paneni_A-Once_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 192.64 kB
Formato Adobe PDF
192.64 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1575960
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact